Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cetylpyridinium chloride · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cetylpyridinium chloride during 21 consecutive days. |
| I | EXPERIMENTAL | Cetylpyridinium chloride during 21 days. |
| Name | Type | Description |
|---|---|---|
| Cetylpyridinium chloride | DRUG | Cetylpyridinium chloride during 21 consecutive days. |
Inclusion Criteria: * Integral buccal mucous (without oral pathologies); * Normal odontological exams; Exclusion Criteria: * Lactation or gestational risk or gestation; * Use of Antiinflammatory or immunosuppression drugs 15 days before the study; * Being in odontological treatment; * Pathologica...
Cetylpyridinium chloride is a small molecule developed by Sanofi (ticker SNY). It has been studied in Phase 3 clinical trials in Brazil, where it was evaluated for safety, dermatological acceptability, and oral hygiene outcomes in healthy volunteers. The specific therapeutic indication for the drug has not been publicly disclosed.
Cetylpyridinium chloride is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 studies of the drug conducted in Brazil. The trials examined safety and acceptability with odontological follow up in healthy volunteer populations.
Cetylpyridinium chloride has been studied in Phase 3 clinical development. Two Phase 3 trials have been completed, and no trials are currently active. The studies were conducted in Brazil and enrolled a combined total of 61 participants.
Cetylpyridinium chloride has been evaluated in two completed Phase 3 trials. NCT00729599 studied safety dermatological evaluation and acceptability with odontological follow up in 31 participants aged 10 years and older. NCT00687037 evaluated safety of the oral mucosa and acceptability with odontological follow up in 30 healthy participants aged 18 and older. Both trials took place in Brazil.
The two completed Phase 3 trials of cetylpyridinium chloride enrolled a combined total of 61 participants. NCT00729599 enrolled 31 participants, and NCT00687037 enrolled 30 participants. Both studies were uncontrolled, non-randomized, and conducted in Brazil with healthy volunteers.